AC Immune (ACIU) Q3 2025 earnings summary

Executive summary

• Strategic review led to sharpened investment focus on high-value assets, including three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau, and alpha-synuclein.

• Workforce reduced by around 30%, extending operational cash runway to end of Q3 2027.

• Multiple value-inflection points expected in Q4 2025, including interim and final results from key clinical trials.

Financial highlights

• Cash resources totaled CHF 108.5 million as of September 30, 2025, down from CHF 165.5 million at year-end 2024.

• Net loss after taxes was CHF 15.9 million for Q3 2025, compared to net income of CHF 5.5 million in Q3 2024, mainly due to a CHF 24.6 million milestone recognized in Q3 2024.

• R&D expenses decreased to CHF 13.1 million from CHF 14.5 million year-over-year, reflecting lower spend on certain programs.

• G&A expenses were CHF 3.6 million, slightly down from CHF 3.8 million year-over-year.

• Restructuring expenses of CHF 0.5 million recognized, including CHF 2.1 million in termination benefits offset by a CHF 1.8 million pension gain.

Outlook and guidance

• Cash runway extended to end of Q3 2027, excluding potential milestone payments.

• Key clinical and regulatory milestones anticipated in Q4 2025, including interim results from Phase 2 trials and IND/CTA filings for new small molecule programs.